Evaluation of usefulness and effectiveness of anxiolytic therapies in neoplastic diseases;Ocena potrzeby i skuteczności leczenia przeciwlȩkowego w chorobach nowotworowych

Polski Merkuriusz Lekarski

Volumn 16, Issue 96, 2004, Pages 561-564

  Ziółko, Ewa ^a,b   Knopik, Jacek ^a   Bucior, Jacek ^a   Foltyn, Wanda ^a   Jastrzȩbska Okoń, Krystyna ^a   Tomczyk, Andrzej ^a   Kempiński, Marcin ^a  

^a Kat/Odd Klin Chorob Wewntrz Sl   (Poland)

^b Kat/Odd Klin Chorob Wewnetrznych   (Poland)

Author keywords

Alprazolam; Anxiety; Diazepam; Oncology

Indexed keywords

AFOBAM; ALPRAZOLAM; ANXIOLYTIC AGENT; DIAZEPAM; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DOCTOR PATIENT RELATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MALE; NEOPLASM; NEUROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; RATING SCALE; TRANQUILIZING ACTIVITY; WILCOXON SIGNED RANKS TEST; ANXIETY; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; AGED; ALPRAZOLAM; ANTI-ANXIETY AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANXIETY; DEPRESSION; DIAZEPAM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 16644383770     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Andersch S., Rosenberg N.K., Kullingsjo H.: Efficacy and safety of alprazolam, imipramine and placebo in treating panic discorder. Acta Psychiatr. Scand., 1991, supl. 365, 18-20.
2. Baraclough J.: Rak i emocje. Wyd. Med. Sanmedica, Warszawa 1997.
3. Beekman A.T.T., de Beurs E., van Balkom A.J.L. i wsp.: Anxiety and depression in later life: co-occurence and communality of risk factors. Am. J. Psychiatry, 2000, 157, 89-92.
4. Casten R.J., Parmelee P.A., Kleban M.H. i wsp.: The relationship among anxiety, depression and pain in a geriatric instutionalized sample. Pain, 1995, 61, 271-274.
5. Czarnecki A., Czlonkowski A., Janiec W. i wsp.: Przewodnik farmakoterapii, 1995, 22-24.
6. de Walden-Gałuszko K.: U kresu. MAKmed, Gdańsk 1996.
7. Eriksson B., Nagy A., Starmark J.E.: Alprazolam compared to amitryptyline in the treatment of major depression. Acta Psychiatr. Scand., 1987, 75, 656-658.
8. Jonas J.M., Cohon M.S.: A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic and depression: a review of the literature. J. Clin. Psychiatr., 1993, 54, supl., 25-45.
9. Kacperczyk J.M.: Lȩk w chorobach somatycznych. Postȩpy Psychiatrii i Neurologii, 1994, 3, 77-79.
10. Kiejnia A., Małyszczak K. Rzewuska M. i wsp.: Alprazolam w leczeniu zaburzeń lȩkowych i lȩkowo-depresyjnych. Psychiatria Polska, 1996, 6, 973-976.
11. Kravitz H.M., Fawcett J., Newman A.J.: Alprazolam and depression: review of risks and benefits. J. Clin. Psychiatry, 1993, 54, suppl., 78-81.
12. Łosiak W.: Poznawcze korelaty lȩku u pacjentów onkologicznych. Prace Psychologiczne. Zesz. Nauk. UJ, 1980, 1, 59-62.
13. O'Sullivan G.H., Noshirvani H., Basoglu M.: Safety and side effects of alprazolam. Controlled study in agoraphobia with panic disorder. Brit. J. Psychiatry, 1994, 164, 79-82.
14. Pecknold J.C.: Discontinuation reactions to alprazolam in panic disorder. J. Psychiatr. Res., 1993, 27, suppl., 1, 155-157.
15. Pużyński S., Berȩsiewicz M.: Zasady rozpoznawania i leczenia zaburzeń psychicznych. Instytut Psychiatrii i Neurologii, Warszawa 1993.
16. Wrześniewski K., Sosnowski T.: Inwentarz stanu i cechy lȩku. Pracownia Testów Psychologicznych, Warszawa 1996.